Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Merck and Moderna post phase 3 cancer vaccine data early
While the primary endpoint hit approached analysts’ best-case scenario, the result was tempered by weaker-than-expected data on a secondary endpoint.
Nick Paul Taylor
,
Fraiser Kansteiner
Oct 22, 2026 4:45pm
Saudi Arabia takes actionable steps to build its biotech sector
Brought to you by
Riyadh Global Medical Biotechnology Summit
Treasury COINS rules add biotech, spares China licensing deals
Oct 22, 2026 11:36pm
The next chapter of CLDN18.2-directed innovation
Brought to you by
Astellas Pharma US
Roche CEO has ‘absolutely not’ changed view on Poseida buyout
Oct 22, 2026 4:16am
Aligning drug discovery around patient benefit from the outset: Connecting human insights to better decisions
Brought to you by
IQVIA Laboratories
More News
Menarini gets Georgiamune preclinical cancer drug in $1B deal
Oct 22, 2026 10:50am
AbbVie posts phase 3 HS win but falls short of expectations
Oct 22, 2026 10:39am
Celltrion picks up another Kaigene antibody for up to $580.5M
Oct 22, 2026 10:22am
Rebranded NodThera plans IPO to fund NLRP3 inhibitor program
Oct 22, 2026 5:27am
See more stories